Union Bancaire Privee UBP SA Lowers Stock Position in Johnson & Johnson $JNJ

Union Bancaire Privee UBP SA reduced its position in shares of Johnson & Johnson (NYSE:JNJ) by 15.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 137,531 shares of the company’s stock after selling 25,119 shares during the period. Union Bancaire Privee UBP SA’s holdings in Johnson & Johnson were worth $33,618,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Blueline Advisors LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $26,000. DecisionPoint Financial LLC increased its position in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares during the last quarter. Bay Harbor Wealth Management LLC lifted its holdings in Johnson & Johnson by 49.0% during the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock worth $31,000 after acquiring an additional 49 shares during the period. Finally, Family CFO Inc purchased a new position in Johnson & Johnson in the fourth quarter worth $31,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on JNJ. Citigroup upped their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the company a “buy” rating in a research note on Tuesday, April 7th. JPMorgan Chase & Co. increased their price target on shares of Johnson & Johnson from $250.00 to $260.00 and gave the company a “neutral” rating in a research report on Wednesday, April 15th. Bank of America raised their price objective on shares of Johnson & Johnson from $253.00 to $254.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, Argus increased their target price on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research report on Thursday, April 16th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.70.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 1.4%

Shares of JNJ opened at $258.24 on Tuesday. The business has a 50-day moving average of $231.39 and a 200 day moving average of $230.03. Johnson & Johnson has a fifty-two week low of $151.52 and a fifty-two week high of $258.58. The firm has a market cap of $621.65 billion, a P/E ratio of 29.85, a price-to-earnings-growth ratio of 2.49 and a beta of 0.26. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion for the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company’s revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. Johnson & Johnson’s dividend payout ratio is currently 61.97%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received a positive CHMP opinion for expanded use of its multiple myeloma drug Tecvayli in combination with Darzalex SC, which could broaden the treatment’s commercial opportunity if approved. Article Title
• Positive Sentiment: JNJ hit a new 52-week high as biotech shares rallied, with investors favoring large-cap healthcare names that have visible pipelines, approvals, and deal-related momentum. Article Title
• Positive Sentiment: Analysts highlighted JNJ’s recent share strength and noted that upward earnings estimate revisions could support additional near-term gains. Article Title
• Positive Sentiment: Johnson & Johnson won another talc-related lawsuit, with a Los Angeles jury finding the company was not negligent in a case involving ovarian cancer claims. Article Title
• Positive Sentiment: Guggenheim raised its price target on JNJ to $270 and reiterated a Buy rating, reflecting continued confidence ahead of the company’s upcoming earnings season. Article Title
• Neutral Sentiment: Commentary about JNJ’s dividend appeal and healthcare sector strength reinforces its status as a stable income stock, but does not add a new fundamental catalyst on its own. Article Title

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.